- Home
- MLSS vs JSPR Comparison
MLSS vs JSPR Comparison
Compare MLSS & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLSS | JSPR |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 23.1M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | MLSS | JSPR |
|---|---|---|
| Price | $0.28 | $0.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $1.00 | ★ $15.50 |
| AVG Volume (30 Days) | 197.7K | ★ 526.7K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,973,982.00 | N/A |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $8.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.99 | N/A |
| 52 Week Low | $0.22 | $0.62 |
| 52 Week High | $1.11 | $7.19 |
Technical Indicators
Market Signals| Indicator | MLSS | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 32.53 |
| Support Level | $0.24 | N/A |
| Resistance Level | $0.31 | $1.44 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 21.69 | 27.79 |
Price Performance
Historical ComparisonAbout MLSS Milestone Scientific Inc.
Milestone Scientific Inc is a biomedical technology company. The company is engaged in pioneering proprietary, technological systems and solutions for the medical and dental markets. The company develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetics. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. The Company conducts its business through two reportable segments: Dental and Medical.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.